A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
about
Gemcitabine for unresectable, locally advanced or metastatic bladder cancerNeoadjuvant cisplatin for advanced bladder cancerNedaplatin: a cisplatin derivative in cancer chemotherapyMuscle-invasive urothelial bladder cancer: an update on systemic therapyRole of systemic chemotherapy in urothelial urinary bladder cancerMultimodal management of muscle-invasive bladder cancerCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Outcome of urinary bladder cancer after combined therapiesBladder cancer in the elderly patient: challenges and solutionsEvidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinomaPlatinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review.A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseA phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urotheliumA phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial.Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.Systemic therapy in bladder cancerA phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.The prognostic value of histological subtype in patients with metastatic bladder cancerChemotherapy and management of bladder tumours.Systemic Therapy for Invasive Bladder Cancer.Progress in the management of metastatic bladder cancer.Recent advances in bladder cancer chemotherapy.Systemic therapy for bladder cancer - a medical oncologist's perspective.First- and second-line therapy for metastatic urothelial carcinoma of the bladderDecreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.Follow-up surveillance strategies for genitourinary malignancies.
P2860
Q24235162-E2897444-5497-4743-838A-0FA0435C0759Q24236721-497431FF-C5ED-4BB4-BE64-0D249754BC49Q24623561-FAB8E0DF-AF38-4345-8F8C-CA96E2C30DABQ26775780-8713C639-2AC5-4B58-8494-872F7986CE30Q27010323-6BBC562E-0B13-4C16-9E93-6BAE6B7FD7ABQ27011624-2CAA9755-2F12-482B-BF5D-17FD7C85315FQ27026717-DE32879A-AC8A-4268-8719-4CA2C92A58FFQ28076180-3B328613-733F-4745-A37F-5539AAB8D329Q28082782-8E517531-570B-4D8D-9B9F-57288FD1FA7DQ28344992-38FF0A31-A248-4DB1-BAE6-D56BB929C581Q28552143-40AA5337-4F96-4BDF-9133-F47183D6BD58Q30240816-8F8322F1-C0FD-47C0-AEFB-E9D73A1C987DQ30275266-A9879299-FC64-417A-A075-38105521CDAEQ30560260-70F64E9A-7155-4FAB-8607-D0A6B5FCDFB3Q32177609-7BE3399B-4657-4D7F-9524-76895FCAB931Q33287243-5AB42C18-4138-45C8-98DF-CF1C3BB2500BQ33330195-2ACEA3FC-6AC2-4D32-B2D0-285203E9C013Q33340282-04F12206-B7F7-418A-A724-4CDAA780F84AQ33342405-6313CFCB-876A-4056-A3B2-E8D25E0FF001Q33344322-FA8FECB7-487A-4735-88B8-50359D1C9DABQ33361999-9174367E-C95B-4FA5-AA39-FA281C5B7354Q33364779-C22A2685-CB6D-4819-9617-44B489BDD510Q33396202-FE16BEDD-4CAE-40EF-8E9C-310AF7D7CE4CQ33399928-5D70E4A9-1D42-4528-9FFF-130847CE9D52Q33405638-87C24ECE-106C-4C15-8A54-84252178371CQ33407440-8521288D-7015-484E-8BDA-8F3901930D08Q33497225-A1D63EEC-F382-4118-B4C0-B74CB4EA7FF4Q33503299-80E0A167-DDA4-4693-9A1F-A333F870FF74Q33578564-24AF7B21-EA9D-4AE8-B360-A14F4F7D47F9Q33621281-21C172B0-C517-406D-AEB6-8D9E0F4DC529Q33662842-DC598C8A-E273-4730-9F6C-6625A4CBC872Q33709712-4BF17A6F-D743-4820-83E5-D60C73A89D56Q33874502-49022672-48BC-4067-BC7B-FD7AE2674218Q33891551-6293B9F5-BDB9-413E-9C76-07A16FD370B5Q33968726-7462BA21-00F0-4749-B327-840C8B4BF8DEQ34211041-91D8FB91-AECA-4BBE-B2C8-693B7BF04610Q34516731-CC9B759C-9D0F-4E82-BFD7-C0C67894EFC4Q34541463-31796096-A5BF-495C-B9F5-69AA627731E5Q34658794-0C946F63-CFCF-479A-AB8F-FA2865D8D05FQ34736606-56FAD157-DD28-45C1-9C56-3923EF9188D4
P2860
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
A randomized comparison of cis ...... ma: a cooperative group study.
@en
type
label
A randomized comparison of cis ...... ma: a cooperative group study.
@en
prefLabel
A randomized comparison of cis ...... ma: a cooperative group study.
@en
P2093
P1476
A randomized comparison of cis ...... ma: a cooperative group study.
@en
P2093
D Raghavan
E D Crawford
L H Einhorn
M F Sarosdy
P J Loehrer
R Stuart-Harris
P304
P356
10.1200/JCO.1992.10.7.1066
P407
P577
1992-07-01T00:00:00Z